SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer

Lung Cancer. 2020 May:143:97-100. doi: 10.1016/j.lungcan.2020.03.017. Epub 2020 Mar 18.

Authors

Li Ma¹, Quan Zhang¹, Yujie Dong², Haoyang Li¹, Jinghui Wang³

Affiliations

¹ Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 97 Ma Chang, Tongzhou District, Beijing, 101149, China.
² Departments of Pathology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
³ Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 97 Ma Chang, Tongzhou District, Beijing, 101149, China. Electronic address: jinghuiwang2006@163.com.

PMID: 32216970
DOI: 10.1016/j.lungcan.2020.03.017

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anaplastic Lymphoma Kinase / genetics*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab / administration & dosage
Calponins
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Crizotinib / administration & dosage
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Oncogene Proteins, Fusion / genetics*
Phosphoproteins / genetics*
Prognosis
Protein Kinase Inhibitors / therapeutic use*

Substances

Anaplastic Lymphoma Kinase
Bevacizumab
Crizotinib
Oncogene Proteins, Fusion
Phosphoproteins
Protein Kinase Inhibitors
SPECC1L protein, human
Calponins
ALK protein, human